Dr. Pirouz M Daftarian is a cellular and molecular immunologist with 20-year experience in Immuno-Oncology and vaccinology. Pirouz has shepherded R&D operations in biotech companies, and academia, acted as DOD and NIH intramural panel reviewer, and is the principal inventor of several IO related regular patents. He has authored more than 60 peer reviewed papers. Pirouz completed his PhD in the Ottawa University, his postdoctoral training in the City of Hope National Medical Centre. Prior to JSR Life Sciences, he has served as a faculty in the University of Dalhousie and Miller School of Medicine University of Miami, and in industry, NGM Biopharmaceutical, Immunovaccine, and Nanovax (as a co-founder). Dr. Daftarian is currently working as the Applications Senior Manager in MBL International leading a team of scientists to develop research tools for shortening the process of R&D and biomarkers for the development of immunotherapeutic and vaccines.
JSR Life Sciences
JSR Life Sciences, and its affiliates, MBL Japan, MBLI, CrownBio, KBI, and Selexis aim to improve R&D and to shorten the drug development process.
In vitro T cell Dysfunction / Exhaustion-Like Assays For Functional Characterization And/Or Screening Of Immunomodulatory Candidate Drugs
The PMWC 2020 Immunotherapy Showcase will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.